Stock SNES SENESTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings SenesTech, Inc.

Equities

SNES

US81720R5054

Market Closed - Nasdaq
Other stock markets
 21:30:01 24/06/2024 BST 		5-day change 1st Jan Change
0.5707 USD -3.21% Intraday chart for SenesTech, Inc. -2.46% -55.06%
05-22 SenesTech, Inc. Launches Evolve?? Fertility Control Solution for Rats on Amazon CI
05-09 SenesTech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SENESTECH, INC. Stock SenesTech, Inc.
-55.06% 2.94M -
MODERNA, INC. Stock Moderna, Inc.
+37.76% 52.5B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.47% 39.01B
B
LONZA GROUP AG Stock Lonza Group AG
+37.72% 39.31B
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.93% 26.2B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-11.17% 26.57B
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+16.45% 28.2B
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.05% 14.15B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+33.13% 12.62B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.46% 11.74B
B+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SNES Stock
  4. Ratings SenesTech, Inc.